Albireo Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Wall St futures tick higher as oil retreats ahead of inflation data
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Birkenstock surges on revenue beat, higher full-year outlook
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Albireo Pharma (ALBO) Misses Q1 EPS by 7c, Revenues Miss
May 9, 2019 7:40 AM EDTAlbireo Pharma (NASDAQ: ALBO) reported Q1 EPS of ($1.39), $0.07 worse than the analyst estimate of ($1.32). Revenue for the quarter came in at $570 thousand versus the consensus estimate of $970 thousand.
For Albireo, 2019 is focused on advancing toward potential approval and launch of odevixibat in its first... More
